ArticlePLOS global public health2026
Burden, clinical impact, and primary antimicrobial resistance profiles of Helicobacter pylori infections in Cameroon: A systematic review and meta-analysis.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori is one of the most widespread pathogens in humans and a strong predictor of gastric cancers. This systematic review and meta-analysis (PROSPERO: CRD420261375391) aimed at determining the extent, clinical impact, and antibiotic resistance profile of H. pylori infections in Cameroon. Six databases were exploited to identify relevant studies published between 2000 and 2026, as per PRISMA guidelines. Pooled proportions were computed using random effects models, while sensitivity analyses were performed to identify confounding factors. A total of 46 studies were included. The pooled proportion of H. pylori infection was 56.7% (95%CI 51.1 - 62.1%), with higher estimates found in i) clinical settings (57.0%), ii) the regions of Centre (62.2%) and Littoral (58.5%), iii) adults (59.7%), and individuals with gastrointestinal disorders (60.1%). The burden of H. pylori was positively correlated with gastric disease severity, with 64.5% of infection cases seen in gastric cancer. Infections have led to adverse clinical effects (e.g., anemia). H. pylori isolates were highly resistant to metronidazole (87.6%, 95%CI 62.4 - 96.8%), while the lowest resistant rates were found for levofloxacin (1.1%, 95%CI 0.4 - 3.2%) and rifampicin (0.6%, 95%CI 0.1 - 2.2%). An unusually high resistance rate to amoxicillin (93.4%; 95% CI 85.9-97.0%) was observed, warranting confirmatory studies. Multidrug-resistant isolates accounted for 77.6%. Several urgent challenges, including the lack of studies in four regions, in other at-risk groups (e.g., obese), limited clinical data, and resistance status vis-à-vis other commonly prescribed ATBs (i.e., amoxicillin), have been identified. This comprehensive study provides baseline data to improve therapeutic management and resistance stewardship in Cameroon.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.